Remodelación inversa del miocardio y reducción de marcadores inflamatorios en pacientes con insuficiencia cardíaca tratada con sacubitrilo/valsartán / Remodelamento reverso do miocárdio e redução de marcadores inflamatórios em pacientes com insuficiência cardíaca tratados com sacubitrilo/valsartan / Reverse myocardial remodeling and reduction of inflammatory markers in patients with heart failure treated with sacubitril/valsartan

Objetivo. Evaluar la evolución de la clase funcional (CF), marcadores de inflamación y función ventricular izquierda en pacientes con miocardiopatía de etiología variada y deterioro severo de la función sistólica luego de seis meses de tratamiento con sacubitrilo/valsartán (S/V). Métodos. Pacientes con fracción de eyección (FE) ≤40%, CF II-IV según NYHA, medicados con S/V y que se encontraban en tratamiento farmacológico instaurado al menos por 3 meses. Se tituló S/V a dosis máxima tolerada junto con beta bloqueantes y antagonistas de los mineralocorticoides. Se realizaron ecocardiograma con medición de FE por método de Simpson's biplano, dosaje de proteína C reactiva (PCR), eritrosedimentación (ES) y un test de caminata de 6 minutos (TC6M) al inicio y a los 6 meses. Se aplicó la prueba estadística T student y la prueba de normalidad Kolmogorov-Smirnov & Shapiro-Wilk. Resultados. Se incluyeron 18 pacientes. El promedio de dosis de S/V fue de 275 mg. Se observó una disminución del diámetro diastólico del ventrículo izquierdo (DDVI) a los 6 meses de 64,54 a 61,41 mm; p=0,05 (3,128; 0,29 a 6,285; IC 95%). El diámetro sistólico del ventrículo izquierdo (DSVI) disminuyó de 51,20 a 43,69 mm; p=0,002 (7,511; 3,292 a 11,730; IC 95%). La FE aumentó de 27,78 a 38,94%; p=0,003 (11,167; 18,081 a 4,252; IC 95%). Los pacientes mejoraron su CF a los 6 meses; p=0,001 (1,111; 0,821 a 1,401; IC 95%). El TC6M aumentó a los 6 meses de 332,22 a 495,00 metros; p=0,001 (162,778; 201,01 a 124,455; IC 95%). También disminuyeron significativamente los niveles de PCR, ES y el números de internaciones. Conclusión. En nuestra población, S/V detuvo la remodelación ventricular generando mejoría de la FE, con reducción de la inflamación sistémica y mejoría en la CF. Estos resultados (prometedores de nuestra pequeña muestra) requieren una nueva evaluación (confirmación) a través de estudios más grandes con períodos de seguimiento más prolongados.

Objective. To evaluate functional class (FC), markers of inflammation and left ventricular function in patients with myocardiopathy of varied etiology and severe deterioration of systolic function after six months of treatment with sacubitril/valsartan (S/V). Methods. Patients with ejection fraction (EF) ≤40% NYHA FC II-IV medicated with S / V and who are in pharmacological treatment established for at least 3 months. It was titled S / V at maximum tolerated dose together with beta-blockers and mineralocorticoid antagonists. We were made echocardiogram with EF measurement by Simpson's biplane method, C-reactive protein (CRP) dose, erythrosedimentation (ES) and a 6-minute walk test (6MWT) at baseline and at 6 months of treatment with S/V. The student's T test and the Kolmogorov-Smirnov & Shapiro-Wilk normality test were applied. Results. We included 18 patients. The mean dose was of S/V 275 mg. A decrease in left ventricular diastolic diameter (LVDD) was observed at 6 months from 64.54 to 61.41 mm; p=0.05 (3.128, 0.29 to 6.285, 95% CI). The left ventricular systolic diameter (LVSD) decreased from 51.20 to 43.69 mm; p=0.002 (7.511, 3.292 to 11.730, 95% CI). The EF increased from 27.78 to 38.94%; p=0.003 (11.167; 18.081 to 4.252; 95% CI). The patients improved their FC at 6 months; p=0.001 (1,111, 0.821 to 1.401, 95% CI). The 6MWT increased after 6 months from 332.22 to 495.00 meters; p=0.001 (162.778; 201.01 to 124.455; 95% CI). Also, the levels of CRP, ES and numbers of hospitalizations decreased significantly. Conclusion. In our population, S/V stopped the ventricular remodeling generating improvement of the EF, with reduction of systemic inflammation and improvement in FC. Promising results from our small sample that requires confirmation larger studies with longer follow-up periods.

Objetivo. Avaliar a evolução da classe funcional (CF), marcadores de inflamação e função ventricular esquerda em pacientes com miocardiopatia de etiologia variada e grave deterioração da função sistólica após seis meses de tratamento com sacubitrilo/valsartan (S/V). Métodos. Pacientes com fração de ejeção (FE) ≤40%, CF II-IV de acordo com a NYHA, medicados com S/V e que estão em tratamento farmacológico estabelecido há pelo menos 3 meses. Foi intitulado S/V na dose máxima tolerada juntamente com beta-bloqueadores e antagonistas mineralocorticoides. Se realizaram ecocardiograma com a medida da FE pelo método biplano de Simpson, dose de proteína C reativa (PCR), eritrosedimentação (ES) e teste de caminhada de 6 minutos (TC6M) no início e aos 6 meses de tratamento com S/V. O teste t de Student e o teste de normalidade de Kolmogorov-Smirnov e Shapiro-Wilk foram aplicados. Resultados. Nós incluímos 18 pacientes. A dose média foi de S/V 275 mg. Observou-se diminuição do diâmetro diastólico do ventrículo esquerdo (DDVE) aos 6 meses de 64,54 para 61,41 mm; p=0,05 (3,128, 0,29 a 6,285, IC 95%). O diâmetro sistólico do ventrículo esquerdo (DSVE) diminuiu de 51,20 para 43,69 mm; p=0,002 (7,511, 3,292 a 11,730, IC 95%). A FE aumentou de 27,78 para 38,94%; p=0,003 (11,167; 18,081 a 4,252; IC 95%). Os pacientes melhoraram sua CF aos 6 meses; p=0,001 (1,111, 0,821 a 1,401, IC 95%). O TC6M aumentou após 6 meses, de 332,22 para 495,00 metros; p=0,001 (162.778; 201,01 a 124,455; IC 95%). Além disso, os níveis de PCR, ES e número de hospitalizações diminuíram significativamente. Conclusão. Em nossa população, a S/V interrompeu o remodelamento ventricular gerando melhora da FE, com redução da inflamação sistêmica e melhora da CF. Estes resultados promissores da nossa pequena amostra exige uma confirmação através de estudos maiores com períodos de acompanhamento mais longos.

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.

Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue regimens, we retrospectively selected 55 NSCLC patients treated with carboplatin/gemcitabine. Pre-treatment formalin fixed biopsies were analyzed for FHIT and p53 protein expression by immunohistochemistry and representative micro dissected tissue for TP53 mutations by DG-DGGE/sequencing. The FHIT-negative immunophenotype (FHIT-, pathologic) was found in 33 patients (60%) and p53 over expression/mutation (p53+, pathologic) in 25 patients (45%). The FHIT-/p53+ combination was present in 12 patients (22%). Overall, there was partial response in 21 patients (38%), with subgroup response rates of 33% in FHIT+/p53-, 46% in FHIT+/p53+, 38% in FHIT-/p53- and 33% in FHIT-/p53+ patients. Median progression-free survival (PFS) was 9.6, 7.9, 6.8 and 5.9 months and median overall survival (OS) was 12.8, 11.9, 10.5 and 8.7 months in the four groups, respectively. The Group comparison showed significantly worse PFS (p=0.04) in FHIT-/p53+ than the other groups. There was no significant difference in OS between the groups. A trend (p=0.07) for shorter OS was found in FHIT- cases suggesting that NSCLC tumors carrying this feature are less responsive to treatment. This retrospective study indicates that FHIT-/p53+ status might be a biological variable influencing the efficacy of carboplatin/gemcitabine treatment in NSCLC.

BIRD: Bio-Image Referral Database. Design and implementation of a new web based and patient multimedia data focused system for effective medical diagnosis and therapy.

This paper presents a low cost software platform prototype supporting health care personnel in retrieving patient referral multimedia data. These information are centralized in a server machine and structured by using a flexible eXtensible Markup Language (XML) Bio-Image Referral Database (BIRD). Data are distributed on demand to requesting client in an Intranet network and transformed via eXtensible Stylesheet Language (XSL) to be visualized in an uniform way on market browsers. The core server operation software has been developed in PHP Hypertext Preprocessor scripting language, which is very versatile and useful for crafting a dynamic Web environment.

[Different degrees of risk of high-frequency atrial fibrillation in symptomatic and asymptomatic WPW syndrome. Electrophysiologic evaluation]. / Diverso rischio di fibrillazione atriale ad alta frequenza nel WPW sintomatico e asintomatico. Valutazione elettrofisiologica.

Sudden death in WPW pattern can occur when atrial fibrillation (a.f.) with rapid ventricular response develops. This event seems to be the final result of three concomitant conditions: the appearance of an orthodromic atrio-ventricular reciprocating tachycardia, the most common form of tachycardia in these patients; a high atrial vulnerability, which makes possible that reciprocating tachycardia degenerates into atrial fibrillation and a short anterograde refractory period of the Kent bundle. With the purpose of evaluating the risk to develop high frequency a.f., 36 WPW subjects were electrophysiologically studied. 22 were symptomatic for palpitations (Group I) and 14 were totally asymptomatic (Group II). 3/22 patients of Group I had experienced clinical atrial fibrillation (Subgroup I A), which was never documented in the remaining 19/22 (Subgroup I B). In all cases the following parameters were analyzed: the presence or absence of the retrograde conduction of the anomalous pathway, essential for the occurrence of orthodromic reciprocating atrio-ventricular tachycardia; the presence or absence of a high atrial vulnerability and the presence of RR intervals between pre-excited complexes during induced a.f. less than 250 msec. As an index of atrial vulnerability were considered the spontaneous degeneration into atrial fibrillation of an electrophysiologically induced reciprocating tachycardia and/or the induction of a sustained a.f. by programmed right atrial stimulation during sinus rhythm and/or during 600 and 400 ms atrial driving and/or by 160-250/m' atrial bursts. Results--Retrograde conduction of Kent bundle was documented in 100% of Gr. I vs 22% of Gr. II (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Secuelas de la interrupción de embarazo / Sequels of pregnancy termination

Se presenta el estudio de 589 gestaciones con el antecedente de un aborto provocado en medio hospitalario en un embarazo anterior. La evaluación y resultados de dichas gestaciones fueron comparadas con tres grupos de control a) con un nacido vivo anterios, b) con un aborto espontáneo anterior, c) primigestas. Los resultados obtenidos demuestran que existe una relación manifiesta entre la interrupción de embarazo anterior y resultados adversos de la siguiente gestación, como son: embarazo ectópico, abortos espontáneos, cesáreas primitivas, crecimiento intrauterino retardado, presentación pelviana y rotura prematura de membranas. Se proponen medidas que tiendan a disminuir tales contingencias